Skip to main content
Skip to "About government"
Skip to section menu
Language selection
Français
fr
/
Gouvernement du Canada
Search
Search Canada.ca
Search
Menu
Main
Menu
Jobs and the workplace
Immigration and citizenship
Travel and tourism
Business and industry
Benefits
Health
Taxes
Environment and natural resources
National security and defence
Culture, history and sport
Policing, justice and emergencies
Transport and infrastructure
Canada and the world
Money and finances
Science and innovation
You are here:
Canada.ca
Departments and agencies
Health Canada
Drugs and health products
Drug products
Scientific/Expert Advisory Panels
ARCHIVED - Opioid Analgesic Abuse (OAA)
We have archived this page and will not be updating it.
You can use it for research or reference.
We have archived this page and will not be updating it.
You can use it for research or reference.
Terms of Reference
2011-02-22
Membership
Membership List and Biographies 2011
Summary of Expertise, Experience and Affiliations and Interests
Meetings
2011-03-29
Agenda
Record of Proceedings
Page details
Report a problem on this page
Date modified:
2011-03-16
Section Menu
Scientific/Expert Advisory Panels
Anti-infective Therapies
Bioequivalence Requirements for Gender-Specific Drug Products (GSDP)
ARCHIVED - Bioequivalence Requirements for Modified-Release Dosage Forms (SAP-MRDF)
Diclectin
ARCHIVED - Opioid Analgesic Abuse (OAA)
Summary of Expertise, Experience and Affiliations and Interests for the Scientific Advisory Panel on Opioid Analgesic Abuse (SAP-OAA)
Scientific Advisory Panel on Opioid Analgesic Abuse (SAP-OAA)
Scientific Advisory Panel on Opioid Use and Contraindications
Scientific Advisory Panel on Opioids (SAP-Opioids)
Scientific/Expert Advisory Panels
Scientific Advisory Committee on Isotretinoin Risk Management (SAP-IRM)
